![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.indianpharmapost.com/news/divis-laboratories-reports-q1-fy25-consolidated-pat-at-rs-430-cr-15974
https://www.reuters.com/business/healthcare-pharmaceuticals/granules-indias-q1-profit-nearly-triples-strong-demand-2024-07-30/
https://www.ndtvprofit.com/business/us-fda-inspects-divis-labs-facility-in-visakhapatnam
https://www.indianpharmapost.com/news/divis-laboratories-to-expand-capacity-at-an-outlay-of-approx-rs-700-cr-15568
https://www.moneycontrol.com/news/business/britannia-most-loved-divis-labs-shunned-by-analysts-in-november-9633531.html
https://www.cnbctv18.com/market/stocks/divis-lab-falls-over-1-as-brokerages-express-concerns-over-growth-sustainability-12482732.htm
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/divis-labs-tumbles-more-than-8-here-is-what-analysts-have-to-say/articleshow/87578556.cms
https://www.channelnewsasia.com/business/indias-divis-labs-hits-record-high-mercks-positive-trial-data-covid-19-drug-2219991
https://www.business-standard.com/article/companies/lack-of-valuation-comfort-may-limit-gains-in-divi-s-laboratories-stock-121080901776_1.html